ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Gastroenterology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

16,443Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 992

$1.49M Total Retail Price of All Prescriptions

Rank: 7 out of 992

1,044 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
85% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 1,044 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

3% of this provider’s 15,924 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

49% of this provider’s prescriptions were for brand-name drugs, compared to an average of 33%.

Prescription Price

$91 was the average price of a prescription from this provider, compared to $139 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 4.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
AMLODIPINE BESYLATE 1,014 985 1 10
NEXIUM 687 675 2 4
ATORVASTATIN CALCIUM 642 608 3 19
SIMVASTATIN 586 586 4 12
OMEPRAZOLE 506 468 5 1
CREON 476 471 6 16
CELEBREX 443 442 7 36
ALENDRONATE SODIUM 424 417 8 31
DEXILANT 399 386 9 5
LOSARTAN POTASSIUM 384 368 10 33
TAMSULOSIN HCL 369 344 11 42
LIDODERM 364 364 12 39
METFORMIN HCL 346 330 13 20
HALFLYTELY-BISACODYL 345 323 10 14 37
LOSARTAN-HYDROCHLOROTHIAZIDE 291 286 15 61
MELOXICAM 272 261 16 46
ACTONEL 269 267 17 75
DIOVAN 261 261 18 35
DIOVAN HCT 258 243 19 49
ZOLPIDEM TARTRATE 237 230 20 32
JANUVIA 204 190 21 73
GLYBURIDE-METFORMIN HCL 203 159 R 22 103
JANUMET 197 197 23 66
ATENOLOL 191 189 24 29
DOXAZOSIN MESYLATE 182 182 25 114
GABAPENTIN 179 174 26 48
CLOPIDOGREL 152 151 27 41
IBANDRONATE SODIUM 150 145 28 97
AZITHROMYCIN 140 134 29 65
LEVOTHYROXINE SODIUM 140 140 29 17
AVODART 140 140 29 89
DONEPEZIL HCL 138 138 32 57
LOVAZA 133 132 33 53
PRAVASTATIN SODIUM 128 128 34 68
EXFORGE 125 125 35 198
LIPITOR 118 118 36 95
PLAVIX 112 112 37 47
PANTOPRAZOLE SODIUM 112 105 37 2
METOPROLOL SUCCINATE 111 108 39 54
LEVOFLOXACIN 105 102 40 94
BENAZEPRIL HCL 105 102 40 67
AZOR 102 102 42 92
LANSOPRAZOLE 99 96 43 28
EVISTA 96 96 44 70
CRESTOR 93 93 45 45
LANTUS SOLOSTAR 93 92 45 217
LYRICA 86 79 47 157
TRIAMCINOLONE ACETONIDE 85 82 48 76
MEGESTROL ACETATE 84 80 R 49 82
CIPROFLOXACIN HCL 82 77 50 63
METOCLOPRAMIDE HCL 80 80 51 18
BYSTOLIC 78 78 52 128
VOLTAREN 78 78 52 86
METFORMIN HCL ER 75 75 54 115
ZENPEP 75 69 54 44
BONIVA 75 68 54 109
HYDROCHLOROTHIAZIDE 72 72 57 51
RANITIDINE HCL 72 67 57 7
TRILIPIX 71 71 59 185
NAMENDA 71 71 59 99
ACIPHEX 70 70 61 40
TRAMADOL HCL 63 63 62 55
AMLODIPINE BESYLATE-BENAZEPRIL 62 60 63 96
NIFEDIPINE ER 57 57 64 140
BENICAR HCT 56 56 65 113
BACLOFEN 55 55 66 158
FUROSEMIDE 54 42 67 30
TRICOR 54 50 67 171
VIREAD 52 41 69 27
DIGOXIN 50 50 70 135
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 5, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.